Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

AHT begins equine herpes virus vaccine research
Equine herpes virus causes respiratory disease, abortion or fatal illness in newborn foals.
Charity to design a modified live virus vaccine 

The Animal Health Trust (AHT) has begun research into developing a new vaccine to protect against equine herpes virus (EHV-1).

Overseen by Dr Neil Bryant, the research comes after the AHT became aware of a pressing need for progress towards a new and improved EHV-1 vaccine.

In March, the Newmarket-based charity was called upon to work with the racing industry and affected parties in dealing with confirmed cases of EHV-1 abortion in Yorkshire and Suffolk. This need led to the development of an Equine Industries EHV Vaccine Steering Group, comprising of world-renowned experts on both human and equine herpes virus.

Chaired by Professor Joe Brownlie of the RVC, the steering group has looked at the existing scientific evidence and agreed the most appropriate way forward is for the AHT to design a modified live virus (MLV) vaccine.

“We’re at the beginning of a very exciting and potentially ground-breaking vaccine development,” said Dr Bryant. “Through our research, we will construct different viruses with attenuating mutations and assess their suitability as MLVs.

“We hope our findings will enable further development by vaccine manufacturers in creating an effective vaccine to protect against the serious clinical signs induced by EHV-1.”

EHV-1 causes respiratory disease, abortion or fatal illness in newborn foals. It also causes neurological disease in adult horses.

Whilst EHV can have severe consequences, there is no vaccine that is licensed to protect against the neurological form of the disease. Existing vaccines do not offer sufficient protection - something that was emphasised in 2016 by the Hertfordshire ‘abortion storm’ in fully vaccinated animals.

“EHV is a major welfare concern for horses and foals and causes emotional, as well as financial strains, on horse owners and breeders around the world,” said Dr Bryant. “It can strike any horse at any time so a vaccine will be of global welfare benefit to all horses, including the Thoroughbred and sports horse breeding industries, and would help control this serious and sometimes fatal disease.”

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.